Patient characteristics
myalgia, GCA, abdominal aortic aneurysm, angina pectoris, claudication, visual impairment, headache, HT
CARDIOVASCULAR DISEASE, SIDE EFFECT, HYPERLIPIDEMIA, CVD, DIABETES MELLITUS, REMISSION, GCA, POLYMYALGIA RHEUMATICA, GIANT CELL ARTERITIS, PMR, HYPERTENSION, DISEASES
The clinical data of the 15 participants are summarized in Clinical background data of the 15 study participants with giant cell arteritis (GCA).AAA, abdominal aortic aneurysm; ACR, 1990 ACR criteria [3]; Angina, angina pectoris; AxA, axillary artery; CCA, common carotid artery; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DMARD, disease-modifying anti-rheumatic drugs; F, Female; HL, hyperlipidemia; HT, hypertension; IFX, infliximab; M, male; MTX, methotrexate; PET, positron emission tomography; ScA, subclavian artery; S, smoker (ongoing); TAB, temporal artery biopsy; TCZ, tocilizumab; US, ultrasound (combined with good response to steroids and exclusion of other diseases at follow-up); XS, ex-smoker.The mean time from GCA diagnosis to initiation of JAKi was 26.9 (range 0−80) months, and the clinical manifestations at the time point of JAKi initiation (baseline) are shown in Individual giant cell arteritis (GCA) features and therapeutic outcomes of JAKi for the 15 study participants.CRP, C-reactive protein; CSx, constitutional symptoms; ESR, erythrocyte sedimentation rate; GCA, giant cell arteritis; HA, headache; JAKi, Janus kinase inhibitor; JC, jaw claudication; PMR, polymyalgia rheumatica; m, months; M, myalgia; NA, not available; VI, visual impairment.JAKi transiently stopped due to the side effect listed.JAKi ended because of sustained remission.